WADA - Listado de sustancias y métodos prohibidos por la agencia mundial antidopaje 2024

WORLD ANTI-DOPING CODE

INTERNATIONAL STANDARD

PROHIBITED

LIST 2024 This List shall come into effect on 1 January 2024. TABLE OF CONTENTS Please note that the list of examples of medical conditions below is not inclusive. SUBSTANCES & METHODS PROHIBITED AT ALL TIMES S0 Non-approved substances.........................................................................................................4 S1 Anabolic agents ...............................................................................................................................5 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. male hypogonadism. S2 Peptide hormones, growth factors, related substances, and mimetics ...........7 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. anaemia, male hypogonadism, growth hormone deficiency. S3 Beta-2 agonists ................................................................................................................................9 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. asthma and other respiratory disorders. S4 Hormone and metabolic modulators ..................................................................................10 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. breast cancer, diabetes, infertility (female), polycystic ovarian syndrome. S5 Diuretics and masking agents................................................................................................12 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. heart failure, hypertension. M1 – M2 – M3 Prohibited Methods.............................................................................................13 SUBSTANCES & METHODS PROHIBITED IN-COMPETITION S6 Stimulants ..........................................................................................................................................14 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. anaphylaxis, attention deficit hyperactivity disorders (ADHD), cold and influenza symptoms. S7 Narcotics ............................................................................................................................................16 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. pain, including from musculoskeletal injuries.

S8 Cannabinoids ...................................................................................................................................17 S9 Glucocorticoids ..............................................................................................................................18 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. allergy, anaphylaxis, asthma, inflammatory bowel disease. SUBSTANCES PROHIBITED IN PARTICULAR SPORTS P1 Beta-blockers ..................................................................................................................................19 Some of these substance(s) may be found, without limitation, in medications used for the treatment of e.g. heart failure, hypertension. INDEX ..................................................................................................................................................................20 2

THE 2024 PROHIBITED LIST

WORLD ANTI-DOPING CODE VALID 1 JANUARY 2024

Introduction The Prohibited List is a mandatory International Standard as part of the World Anti-Doping Program. The List is updated annually following an extensive consultation process facilitated by WADA. The effective date of the List is 01 January 2024. The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. Below are some terms used in this List of Prohibited Substances and Prohibited Methods. Prohibited In-Competition Subject to a different period having been approved by WADA for a given sport, the In-Competition period shall in principle be the period commencing just before midnight (at 11:59 p.m.) on the day before a Competition in which the Athlete is scheduled to participate until the end of the Competition and the Sample collection process. Prohibited at all times This means that the substance or method is prohibited Inand Out-of-Competition as defined in the Code. Specified and non-Specified As per Article 4.2.2 of the World Anti-Doping Code, “for purposes of the application of Article 10, all Prohibited Substances shall be Specified Substances except as identified on the Prohibited List. No Prohibited Method shall be a Specified Method

unless it is specifically identified as a Specified Method on the Prohibited List”. As per the comment to the article, “the Specified Substances and Methods identified in Article 4.2.2 should not in any way be considered less important or less dangerous than other doping substances or methods. Rather, they are simply substances and methods which are more likely to have been consumed or used by an Athlete for a purpose other than the enhancement of sport performance.” Substances of Abuse Pursuant to Article 4.2.3 of the Code, Substances of Abuse are substances that are identified as such because they are frequently abused in society outside of the context of sport. The following are designated Substances of Abuse: cocaine, diamorphine (heroin), methylenedioxymethamphetamine (MDMA/”ecstasy”), tetrahydrocannabinol (THC).

Published by: World Anti-Doping Agency Stock Exchange Tower 800 Place Victoria (Suite 1700) URL: www.wada-ama.org PO Box 120 Tel: +1 514 904 9232

Montreal, Quebec Fax: +1 514 904 8650 Canada H4Z 1B7 E-mail: code@wada-ama.org 3 S0 NON-APPROVED SUBSTANCES PROHIBITED AT ALL TIMES (INAND OUT-OF-COMPETITION) All prohibited substances in this class are Specified Substances. Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times. This class covers many different substances including but not limited to BPC-157, 2,4Dinitrophenol (DNP) and Troponin Activators (e.g. Reldesemtiv and Tirasemtiv).

4 S1 ANABOLIC AGENTS PROHIBITED AT ALL TIMES (INAND OUT-OF-COMPETITION) All prohibited substances in this class are non-Specified Substances. Anabolic agents are prohibited. S1.1. ANABOLIC ANDROGENIC STEROIDS (AAS) When administered exogenously, including but not limited to: • 1-Androstenediol (5ɑ-androst-1-ene-3ß, • Androstenedione (androst-4-ene-3,17-dione) 17ß-diol) • Bolasterone • 1-Androstenedione (5ɑ-androst-1-ene-3, • Boldenone 17-dione) • Boldione (androsta-1,4-diene-3,17-dione) • 1-Androsterone (3ɑ-hydroxy-5a-androst-1ene-17-one) • Calusterone • 1-Epiandrosterone (3ß-hydroxy-5ɑ-androst- • Clostebol 1-ene-17-one) • D anazol ([1,2]oxazolo[4’,5’:2,3]pregna-4-en- • 1-Testosterone (17ß-hydroxy-5ɑ-androst-120-yn-17ɑ-ol) en-3-one) • Dehydrochlormethyltestosterone (4-chloro- • 4-Androstenediol (androst-4-ene-3ß, 17ß-hydroxy-17ɑ-methylandrosta-1,4-dien-3one) 17ß-diol) • 4-Hydroxytestosterone • Desoxymethyltestosterone (17ɑ-methyl- (4,17ß-dihydroxyandrost-4-en-3-one) 5ɑ-androst-2-en-17ß-ol and 17ɑ-methyl-5ɑ-

androst-3-en-17ß-ol) • 5-Androstenedione (androst-5-ene-3,17-dione) • Dimethandrolone (7ɑ,11ß-Dimethyl-19- • 7ɑ-Hydroxy-DHEA nortestosterone) • 7ß-Hydroxy-DHEA • Drostanolone • 7-Keto-DHEA • Epiandrosterone (3ß-hydroxy-5ɑ-androstan- • 11ß-Methyl-19-nortestosterone 17-one) • 17ɑ-Methylepithiostanol (epistane) • Epi-dihydrotestosterone (17ß-hydroxy-5ß- androstan-3-one) • 19-Norandrostenediol (estr-4-ene-3,17-diol) • 19-Norandrostenedione (estr-4-ene-3,17-dione) • Epitestosterone • Androst-4-ene-3,11,17trione • Ethylestrenol (19-norpregna-4-en-17ɑ-ol) (11-ketoandrostenedione, adrenosterone) • F luoxymesterone • Androstanolone (5ɑ-dihydrotestosterone, • F ormebolone 17ß-hydroxy-5ɑ-androstan-3-one) • Furazabol (17ɑ-methyl [1,2,5] • Androstenediol (androst-5-ene-3ß,17ß-diol) oxadiazolo[3’,4’:2,3]-5ɑ-androstan-17ß-ol) 5 S1

ANABOLIC AGENTS

(continued) S1.1. ANABOLIC ANDROGENIC STEROIDS (AAS) (continued) • G estrinone • Norclostebol (4-chloro-17ß-ol-estr-4-en-3-one)

• Mestanolone • Norethandrolone • Mesterolone • Oxabolone • Metandienone (17ß-hydroxy-17ɑ- • O xandrolone methylandrosta-1,4-dien-3-one) • Oxymesterone • Metenolone • O xymetholone • M ethandriol • Prasterone (dehydroepiandrosterone, DHEA, • Methasterone (17ß-hydroxy-2ɑ,17ɑ-dimethyl3ß-hydroxyandrost-5-en-17-one) 5ɑ-androstan-3-one) • Prostanozol (17ß-[(tetrahydropyran-2-yl)oxy]- • Methyl-1-testosterone (17ß-hydroxy-17ɑ- 1’H-pyrazolo[3,4:2,3]-5ɑ-androstane) methyl-5ɑ-androst-1-en-3-one) • Quinbolone • Methylclostebol • S tanozolol • Methyldienolone (17ß-hydroxy-17ɑ- • Stenbolone methylestra-4,9-dien-3-one) • Testosterone • Methylnortestosterone (17ß-hydroxy-17ɑ- methylestr-4-en-3-one) • Tetrahydrogestrinone (17-hydroxy-18ahomo-19-nor-17ɑ-pregna-4,9,11-trien-3-one)
• Methyltestosterone • Tibolone • Metribolone (methyltrienolone, 17ß-hydroxy17ɑ-methylestra-4,9,11-trien-3-one) • Trenbolone (17ß-hydroxyestr-4,9,11-trien-3one) • Mibolerone • Trestolone (7ɑ-Methyl-19-nortestosterone, • Nandrolone (19-nortestosterone) MENT) • Norboletone and other substances with a similar chemical structure or similar biological effect(s).

S1.2. OTHER ANABOLIC AGENTS Including, but not limited to: Clenbuterol, osilodrostat, ractopamine, selective androgen receptor modulators [SARMs, e.g. andarine, enobosarm (ostarine), LGD-4033 (ligandrol), RAD140, S-23 and YK-11], zeranol and zilpaterol. 6 S2

PEPTIDE HORMONES,

GROWTH FACTORS, RELATED

SUBSTANCES, AND MIMETICS PROHIBITED AT ALL TIMES (INAND OUT-OF-COMPETITION) All prohibited substances in this class are non-Specified Substances. The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited. S2.1. ERYTHROPOIETINS (EPO) AND AGENTS AFFECTING ERYTHROPOIESIS Including, but not limited to: S2.1.1 Erythropoietin receptor agonists, e.g. darbepoetins (dEPO); erythropoietins (EPO); EPO-based constructs [e.g. EPO-Fc, methoxy polyethylene glycol-epoetin beta (CERA)]; EPO-mimetic agents and their constructs (e.g. CNTO-530, peginesatide). S2.1.2 Hypoxia-inducible factor (HIF) activating agents, e.g. cobalt; daprodustat (GSK1278863); IOX2; molidustat (BAY 85-3934); roxadustat (FG-4592); vadadustat (AKB-6548); xenon.

S2.1.3 GATA inhibitors, e.g. K-11706. S2.1.4 Transforming growth factor beta (TGF-ß) signalling inhibitors, e.g. luspatercept; sotatercept. S2.1.5 Innate repair receptor agonists, e.g. asialo EPO; carbamylated EPO (CEPO). 7 S2

PEPTIDE HORMONES,

GROWTH FACTORS, RELATED

SUBSTANCES, AND MIMETICS

(continued) S2.2. PEPTIDE HORMONES AND THEIR RELEASING FACTORS S2.2.1 Testosterone-stimulating peptides in males including, but not limited to: • chorionic gonadotrophin (CG), • luteinizing hormone (LH), • gonadotrophinreleasing hormone (GnRH, gonadorelin) and its agonist analogues (e.g. buserelin, deslorelin, goserelin, histrelin, leuprorelin, nafarelin and triptorelin), • kisspeptin and its agonist analogues S2.2.2 Corticotrophins and their releasing factors, e.g. corticorelin and tetracosactide S2.2.3 Growth hormone (GH), its analogues and fragments including, but not limited to: • growth hormone analogues, e.g. lonapegsomatropin, somapacitan and somatrogon • growth hormone fragments, e.g. AOD-9604 and hGH 176-191 S2.2.4 Growth hormone releasing factors, including, but not limited to: • growth hormone-releasing hormone (GHRH) and its analogues (e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin) • growth hormone secretagogues (GHS) and their mimetics [e.g. anamorelin,

capromorelin, ibutamoren (MK-677), ipamorelin, lenomorelin (ghrelin), macimorelin and tabimorelin] • GH-releasing peptides (GHRPs) [e.g. alexamorelin, examorelin (hexarelin), GHRP-1, GHRP-2 (pralmorelin), GHRP-3, GHRP-4, GHRP-5 and GHRP-6] S2.3. GROWTH FACTORS AND GROWTH FACTOR MODULATORS Including, but not limited to: • Fibroblast growth factors (FGFs) • Hepatocyte growth factor (HGF) • Insulin-like growth factor 1 (IGF-1, mecasermin) and its analogues • Mechano growth factors (MGFs) • Platelet-derived growth factor (PDGF) • Thymosin-ß4 and its derivatives e.g. TB-500 • Vascular endothelial growth factor (VEGF) and other growth factors or growth factor modulators affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching. 8 S3 BETA-2 AGONISTS PROHIBITED AT ALL TIMES (INAND OUT-OF-COMPETITION) All prohibited substances in this class are Specified Substances. All selective and non-selective beta-2 agonists, including all optical isomers, are prohibited. Including, but not limited to: • Arformoterol • Indacaterol • Reproterol • Tretoquinol (trimetoquinol) • Fenoterol • Levosalbutamol • Salbutamol • Formoterol • Olodaterol • Salmeterol • Tulobuterol • Higenamine • Procaterol • Terbutaline • Vilanterol EXCEPTIONS • Inhaled salbutamol: maximum 1600 micrograms over 24 hours in divided doses not to

exceed 600 micrograms over 8 hours starting from any dose; • Inhaled formoterol: maximum delivered dose of 54 micrograms over 24 hours; • Inhaled salmeterol: maximum 200 micrograms over 24 hours; • Inhaled vilanterol: maximum 25 micrograms over 24 hours. NOTE The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40 ng/mL is not consistent with therapeutic use of the substance and will be considered as an Adverse Analytical Finding (AAF) unless the Athlete proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of a therapeutic dose (by inhalation) up to the maximum dose indicated above. 9 S4

HORMONE AND

METABOLIC MODULATORS PROHIBITED AT ALL TIMES (INAND OUT-OF-COMPETITION) Prohibited substances in classes S4.1 and S4.2 are Specified Substances. Those in classes S4.3 and S4.4 are non-Specified Substances. The following hormone and metabolic modulators are prohibited. S4.1. AROMATASE INHIBITORS Including, but not limited to: • 2-Androstenol (5ɑ-androst-2-en-17-ol) • Androsta-1,4,6-triene-3,17-dione (androstatrienedione) • 2-Androstenone (5ɑ-androst-2-en-17-one) • 3-Androstenol (5ɑ-androst-3-en-17-ol) • Androsta-3,5-diene-7,17-dione (arimistane) • 3-Androstenone (5ɑ-androst-3-en-17-one) • Exemestane • 4-Androstene-3,6,17 trione (6-oxo) • Formestane

• Aminoglutethimide • Letrozole • Anastrozole • Testolactone

S4.2. ANTI-ESTROGENIC SUBSTANCES [ANTI-ESTROGENS AND

SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS)] Including, but not limited to: • Bazedoxifene • Fulvestrant • Tamoxifen • Clomifene • Ospemifene • Toremifene • Cyclofenil • Raloxifene 10 S4

HORMONE AND

METABOLIC MODULATORS

(continued) S4.3. AGENTS PREVENTING ACTIVIN RECEPTOR IIB ACTIVATION Including, but not limited to: • Activin A-neutralizing antibodies • Myostatin inhibitors such as: • Activin receptor IIB competitors such as: – Agents reducing or ablating myostatin expression – Decoy activin receptors (e.g. ACE-031) – Myostatin-binding proteins • Anti-activin receptor IIB antibodies (e.g. follistatin, myostatin propeptide) (e.g. bimagrumab) – Myostatinor precursor-neutralizing antibodies (e.g. apitegromab, domagrozumab, landogrozumab, stamulumab) S4.4. METABOLIC MODULATORS S4.4.1 Activators of the AMP-activated protein kinase (AMPK), e.g. AICAR, peroxisome proliferator-activated receptor delta (PPARδ) agonists, e.g. 2-(2-methyl-4-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methylthio) phenoxy) acetic acid (GW1516, GW501516) and Rev-erbɑ agonists, e.g. SR9009, SR9011 S4.4.2 Insulins and insulin-mimetics

S4.4.3 Meldonium S4.4.4 Trimetazidine 11 S5

DIURETICS AND

MASKING AGENTS PROHIBITED AT ALL TIMES (INAND OUT-OF-COMPETITION) All prohibited substances in this class are Specified Substances. All diuretics and masking agents, including all optical isomers, e.g. dand lwhere relevant, are prohibited. Including, but not limited to: • Diuretics such as: Acetazolamide; amiloride; bumetanide; canrenone; chlortalidone; etacrynic acid; furosemide; indapamide; metolazone; spironolactone; thiazides, e.g. bendroflumethiazide, chlorothiazide and hydrochlorothiazide; torasemide; triamterene; • Vaptans, e.g. conivaptan, mozavaptan, tolvaptan; • Plasma expanders by intravenous administration such as: Albumin, dextran, hydroxyethyl starch, mannitol;

• Desmopressin; • Probenecid; and other substances with a similar chemical structure or similar biological effect(s).

EXCEPTIONS • Drospirenone; pamabrom; and topical ophthalmic administration of carbonic anhydrase inhibitors (e.g. dorzolamide, brinzolamide); • Local administration of felypressin in dental anaesthesia. NOTE The detection in an Athlete’s Sample at all times or In-Competition, as applicable, of any quantity of the following substances subject to threshold limits: formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine, in conjunction with a diuretic or masking agent (except topical ophthalmic administration of a carbonic anhydrase inhibitor or local administration of felypressin in dental anaesthesia), will be considered

as an Adverse Analytical Finding (AAF) unless the Athlete has an approved Therapeutic Use Exemption (TUE) for that substance in addition to the one granted for the diuretic or masking agent. 12 PROHIBITED METHODS PROHIBITED AT ALL TIMES (INAND OUT-OF-COMPETITION) All prohibited methods in this class are non-Specified except methods in M2.2. which are Specified Methods. M1. MANIPULATION OF BLOOD AND BLOOD COMPONENTS The following are prohibited: M1.1. The Administration or reintroduction of any quantity of autologous, allogenic (homologous) or heterologous blood, or red blood cell products of any origin into the circulatory system except donation by Athletes of plasma or plasma components by plasmapheresis performed in a registered collection center. M1.2. Artificially enhancing the uptake, transport or delivery of oxygen. Including, but not limited to: Perfluorochemicals; efaproxiral (RSR13); voxelotor and modified haemoglobin products, e.g. haemoglobin-based blood substitutes and microencapsulated haemoglobin products, excluding supplemental oxygen by inhalation. M1.3. Any form of intravascular manipulation of the blood or blood components by physical or chemical means. M2. CHEMICAL AND PHYSICAL MANIPULATION The following are prohibited: M2.1. Tampering, or Attempting to Tamper, to alter the integrity and validity of Samples collected during Doping Control. Including, but not limited to: Sample substitution and/or adulteration, e.g. addition of proteases to Sample. M2.2. Intravenous infusions and/or injections of more than a total of 100 mL per 12-hour period except for those legitimately received in the course of hospital treatments, surgical procedures or clinical diagnostic investigations. M3. GENE AND CELL DOPING The following, with the potential to enhance sport performance, are prohibited:

M3.1. The use of nucleic acids or nucleic acid analogues that may alter genome sequences and/or alter gene expression by any mechanism. This includes but is not limited to gene editing, gene silencing and gene transfer technologies. M3.2. The use of normal or genetically modified cells. 13 S6 STIMULANTS PROHIBITED IN-COMPETITION All prohibited substances in this class are Specified Substances except those in S6.A, which are non-Specified Substances. Substances of Abuse in this section: cocaine and methylenedioxymethamphetamine (MDMA / “ecstasy”) All stimulants, including all optical isomers, e.g. dand lwhere relevant, are prohibited.

Stimulants include: S6.A: NON-SPECIFIED STIMULANTS • Adrafinil • Fonturacetam

[4-phenylpiracetam (carphedon)] • Amfepramone • Amfetamine • Furfenorex • Amfetaminil • Lisdexamfetamine • Amiphenazole • Mefenorex • Benfluorex • Mephentermine • Benzylpiperazine • Mesocarb • Bromantan • Metamfetamine(d-) • Clobenzorex • p-methylamfetamine • Cocaine • Modafinil • Cropropamide • Norfenfluramine • Crotetamide • Phendimetrazine • Fencamine • Phentermine • Fenetylline • Prenylamine • Fenfluramine • Prolintane • Fenproporex A stimulant not expressly listed in this section is a Specified Substance. 14 S6

STIMULANTS

(continued) S6.B: SPECIFIED STIMULANTS Including, but not limited to: • 2-phenylpropan-1-amine • Epinephrine • Nikethamide

(ß-methylphenylethyl- (adrenaline) • Norfenefrine amine, BMPEA) • Etamivan • Octodrine (1,5-dimethyl- • 3-Methylhexan-2-amine • Ethylphenidate hexylamine) (1,2-dimethylpentylamine) • Etilamfetamine • Octopamine • 4-Fluoromethylphenidate • Etilefrine • Oxilofrine • 4-Methylhexan-2-amine (methylsynephrine)

• Famprofazone (1,3-dimethylamylamine, 1,3 DMAA, methylhexanea- • Fenbutrazate • Pemoline mine) • Fencamfamin • Pentetrazol • 4-Methylpentan-2-amine • Heptaminol • Phenethylamine (1,3-dimethylbutylamine) and its derivatives • Hydrafinil (fluorenol) • 5-Methylhexan-2-amine • Phenmetrazine • Hydroxyamfetamine (1,4-dimethylamylamine, (parahydroxyamphet- • Phenpromethamine 1,4-dimethylpentylamine, amine) • Propylhexedrine 1,4-DMAA) • Isometheptene • Pseudoephedrine • Benzfetamine • Levmetamfetamine • Selegiline • Cathine • Meclofenoxate • Sibutramine • Cathinone and its analogues, e.g. mephedrone, • Methylenedioxymetham- • Solriamfetol methedrone, and ɑ - phetamine • Strychnine pyrrolidinovalerophenone • Methylephedrine • Tenamfetamine

• Dimetamfetamine • Methylnaphthidate (methylenedioxyamphet-

(dimethylamphetamine) [(±)-methyl-2-(naphthalen-2amine) • Ephedrine yl)-2-(piperidin-2-yl)acetate] • Tuaminoheptane • Methylphenidate and other substances with a similar chemical structure or similar biological effect(s). EXCEPTIONS • Clonidine; • Imidazoline derivatives for dermatological, nasal, ophthalmic or otic use (e.g. brimonidine, clonazoline, fenoxazoline, indanazoline, naphazoline, oxymetazoline, tetryzoline, tramazoline, xylometazoline) and those stimulants included in the 2024 Monitoring Program. Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol, and synephrine: These substances are included in the 2024 Monitoring Program and are not considered Prohibited Substances. C athine (d-norpseudoephedrine) and its l-isomer: Prohibited when its concentration in urine is greater than 5 micrograms per millilitre. Ephedrine and methylephedrine: Prohibited when the concentration of either in urine is greater than 10 micrograms per millilitre. Epinephrine (adrenaline): Not prohibited in local administration, e.g. nasal, ophthalmologic, or co-administration with local anaesthetic agents. Pseudoephedrine: Prohibited when its concentration in urine is greater than 150 micrograms per millilitre. 15 S7 NARCOTICS PROHIBITED IN-COMPETITION All prohibited substances in this class are Specified Substances. Substance of Abuse in this section: diamorphine (heroin) The following narcotics, including all optical isomers, e.g. dand lwhere relevant,

are prohibited. • Buprenorphine • Fentanyl and its • Morphine • Pentazocine derivatives • Dextromoramide • Nicomorphine • Pethidine • Diamorphine • Hydromorphone • Oxycodone • Tramadol (heroin) • Methadone • Oxymorphone 16 S8 CANNABINOIDS PROHIBITED IN-COMPETITION All prohibited substances in this class are Specified Substances. Substance of Abuse in this section: tetrahydrocannabinol (THC) All natural and synthetic cannabinoids are prohibited, e.g. • In cannabis (hashish, marijuana) and cannabis products • Natural and synthetic tetrahydrocannabinols (THCs) • Synthetic cannabinoids that mimic the effects of THC

EXCEPTIONS

• Cannabidiol

17 S9 GLUCOCORTICOIDS PROHIBITED IN-COMPETITION All prohibited substances in this class are Specified Substances. All glucocorticoids are prohibited when administered by any injectable, oral [including oromucosal (e.g. buccal, gingival, sublingual)] or rectal route. Including, but not limited to: • Beclometasone • Dexamethasone • Mometasone • Betamethasone • Flunisolide • Prednisolone • Budesonide • Fluocortolone • Prednisone • Ciclesonide • Fluticasone • Triamcinolone acetonide • Cortisone • Hydrocortisone • Deflazacort • Methylprednisolone NOTE • Other routes of administration (including inhaled, and topical: dental-intracanal, dermal, intranasal, ophthalmological, otic and perianal) are not prohibited when used within the manufacturer’s licensed doses and therapeutic indications. 18 P1

BETA-BLOCKERS

PROHIBITED IN PARTICULAR SPORTS

All prohibited substances in this class are Specified Substances. Beta-blockers are prohibited In-Competition only, in the following sports, and also prohibited Out-of-Competition where indicated (). • Archery (WA) • Skiing/Snowboarding (FIS) in ski jumping, freestyle aerials/halfpipe and snowboard • Automobile (FIA) halfpipe/big air • Billiards (all disciplines) (WCBS) • Underwater sports (CMAS) in all • Darts (WDF) subdisciplines of freediving, spearfishing • Golf (IGF) and target shooting • Mini-Golf (WMF) • Shooting (ISSF, IPC) Also prohibited Out-of-Competition Including, but not limited to: • Acebutolol • Bunolol • Labetalol • Oxprenolol • Alprenolol • Carteolol • Metipranolol • Pindolol • Atenolol • Carvedilol • Metoprolol • Propranolol • Betaxolol • Celiprolol • Nadolol • Sotalol • Bisoprolol • Esmolol • Nebivolol • Timolol 19 INDEX (±)-Methyl-2-(naphthalen-2-yl)-27ß-Hydroxy-DHEA, 5 Amfepramone, 14 (piperidin-2-yl)acetate, 15 7-Keto-DHEA, 5 Amfetamine, 14 1-Androstenediol, 5 11ß-Methyl-19-nortestosterone, 5 Amfetaminil, 14 1-Androstenedione, 5 11-Ketoandrostenedione, 5 Amiloride, 12 1-Androsterone, 5 17ɑ-Methyl [1,2,5]oxadiazolo[3’,4’:2,3]- Aminoglutethimide, 10

1-Epiandrosterone, 5 5ɑ-androstan-17ß-ol, 5 Amiphenazole, 14 1-Testosterone, 5 17ɑ-Methyl-5ɑ-androst-2-en-17ß-ol, 5 AMP-activated protein kinase (AMPK), 11 1,2-Dimethylpentylamine, 15 17ɑ-Methyl-5ɑ-androst-3-en-17ß-ol, 5 Anamorelin, 8 [1,2]Oxazolo[4’,5’:2,3]pregna-4-en-2017ɑ-Methylepithiostanol, 5 Anastrozole, 10 yn-17ɑ-ol), 5 17ß-Hydroxy-2ɑ,17ɑ-dimethyl-5ɑ- Andarine, 6 1,3-Dimethylamylamine (1,3 DMAA), 15 androstan-3-one, 6 Androst-4-ene-3ß,17ß-diol, 5 1,3-Dimethylbutylamine, 15 17ß-Hydroxy-5ɑ-androst-1-en-3-one, 5 Androst-4-ene-3,11,17trione, 5 1,4-Dimethylamylamine (1,4-DMAA), 15 17ß-Hydroxy-5ɑ-androstan-3-one, 5 Androst-4-ene-3,17-dione, 5 1,4-Dimethylpentylamine, 15 17ß-Hydroxy-5ß-androstan-3-one, 5 Androst-5-ene-3ß,17ß-diol, 5 1,5Dimethyl-hexylamine, 15 17ß-hydroxy-17ɑ-methyl-5ɑ-androst-1Androst-5-ene-3,17-dione, 5

2-Androstenol, 10 en-3-one, 6 Androsta-1,4,6-triene-3,17-dione, 10 2-Androstenone, 10 17ß-Hydroxy-17ɑ-methylandrosta-1,4dien-3-one, 6 Androsta-1,4-diene-3,17-dione, 5 2-Phenylpropan-1-amine, 15 2,4-Dinitrophenol (DNP), 4 17ß-Hydroxy-17ɑ-methylestr-4-en-3Androsta-3,5-diene-7,17-dione, 10 one, 6 Androstanolone, 5 3ɑ-Hydroxy-5ɑ-androst-1-ene-17-one, 5 17ß-Hydroxy-17ɑ-methylestra-4,9-dienAndrostatrienedione, 10 3ß-Hydroxy-5ɑ-androst-1-ene-17-one, 5 3-one, 6 Androstenediol, 5 3ß-Hydroxy-5ɑ-androstan-17-one, 5 17ß-Hydroxy-17ɑ-methylestra-4,9,11Androstenedione, 5 3ß-Hydroxyandrost-5-en-17-one, 6 trien-3-one, 6 Anti-activin receptor IIB antibodies, 11 3-Androstenol, 10 17ß-Hydroxyestr-4,9,11-trien-3-one, 6 AOD-9604, 8 3-Androstenone, 10 17ß-[(Tetrahydropyran-2-yl)oxy]-1’HApitegromab, 11 3-Methylhexan-2-amine, 15 pyrazolo[3,4:2,3]-5ɑ-androstane, 6

Arformoterol, 9 4-Androstene-3,6,17 trione, 10 17-Hydroxy-18a-homo-19-nor-17ɑ- Arimistane, 10 4-Androstenediol, 5 pregna-4,9,11-trien-3-one, 6 Asialo EPO, 7 4-Chloro-17ß-hydroxy-17ɑ- 19-Norandrostenediol, 5 methylandrosta-1,4-dien-3-one, 5 Atenolol, 19 19-Norandrostenedione, 5 4-Chloro-17ß-ol-estr-4-en-3-one, 6 19-Norpregna-4-en-17ɑ-ol, 5 B 4-Fluoromethylphenidate, 15 19-Nortestosterone, 6 4-Hydroxytestosterone, 5 Bazedoxifene, 10 ɑ-Pyrrolidinovalerophenone, 15 4-Methylhexan-2-amine, 15 Beclometasone, 18 ß-Methylphenylethylamine, 15 4-Methylpentan-2-amine, 15 Bendroflumethiazide, 12 4-Phenylpiracetam, 14 A Benfluorex, 14 4,17ß-Dihydroxyandrost-4-en-3-one, 5 Benzfetamine, 15 ACE-031, 11 5ɑ-Androst-1-ene-3, 17-dione, 5 Benzylpiperazine, 14 Acebutolol, 19 5ɑ-Androst-1-ene-3ß, 17ß-diol, 5 Betamethasone, 18 Acetazolamide, 12 5ɑ-Androst-2-en-17-ol, 10 Betaxolol, 19

Activators of the AMP-activated 5ɑ-Androst-2-en-17-one, 10 protein kinase (AMPK), 11 Bimagrumab, 11 5ɑ-Androst-3-en-17-ol, 10 Activin A-neutralizing antibodies, 11 Bisoprolol, 19 5ɑ-Androst-3-en-17-one, 10 Activin receptor IIB competitors, 11 Blood, 13 5ɑ-Dihydrotestosterone, 5 Adrafinil, 14 Blood (autologous), 13 5-Androstenedione, 5 Adrenaline, 15 Blood (components), 13 5-Methylhexan-2-amine, 15 Adrenosterone, 5 Blood (heterologous), 13 6-Oxo, 10 AICAR, 11 Blood (homologous), 13 7ɑ-Hydroxy-DHEA, 5 Albumin, 12 Blood manipulation, 13 7ɑ,11ß-Dimethyl-19-nortestosterone, 5 Alexamorelin, 8 BMPEA, 15 7ɑ-Methyl-19-nortestosterone, 6 Alprenolol, 19 Bolasterone, 5 20 INDEX Boldenone, 5 Cortisone, 18 Etilamfetamine, 15 Boldione, 5 Cropropamide, 14 Etilefrine, 15 BPC-157, 4 Crotetamide, 14 Examorelin, 8 Brimonidine, 15 Cyclofenil, 10 Exemestane, 10 Brinzolamide, 12 D F Bromantan, 14 Budesonide, 18 Danazol, 5 Famprofazone, 15 Bumetanide, 12 Daprodustat, 7 Felypressin, 12 Bunolol, 19 Darbepoetins (dEPO), 7 Fenbutrazate, 15

Buprenorphine, 16 Deflazacort, 18 Fencamfamin, 15 Bupropion, 15 Dehydrochlormethyltestosterone, 5 Fencamine, 14 Buserelin, 8 Dehydroepiandrosterone (DHEA), 6 Fenetylline, 14 Deslorelin, 8 Fenfl